ascopubs.org11d
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...
ascopubs.org20d
Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study.
Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...
ascopubs.org11d
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...
ascopubs.org18d
Erratum: Development and Implementation of a Geriatric Oncology Interdisciplinary Case–Based Educational Intervention for Cancer Care Providers
Erratum: Genetic Signatures: CD44 Single-Nucleotide Polymorphisms Affect Cell Surface Expression and Elevate Risk in Head and Neck Squamous Cell Carcinoma The article by Verduzco-Aguirre et al ...
ascopubs.org4d
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Anti–vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis. Thirty-seven ...
ascopubs.org18d
Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study
We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those ...
ascopubs.org20d
Impact of upstaging from cT2a–b to pT3a on overall survival (OS) among patients with renal cell carcinoma.
Concordance between clinical and pathologic staging of T2a–b and T3a renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...
ascopubs.org20d
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Casdatifan (Cas) monotherapy in ...
ascopubs.org4d
Recent Developments in the Management of Renal Cell Cancer
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) The management of renal cell carcinoma (RCC) has seen significant ...
ascopubs.org10d
Somatic Landscape of Oncogenic Variants Across the Main Cancer Subtypes in Latin America: A Narrative Review
Evolution and Recent Radiation Therapy Advancement in Uganda: A Precedent on How to Increase Access to Quality Radiotherapy Services in Low- and Middle-Income Countries Variations in somatic genetic ...
ascopubs.org10d
Challenges in the Management of Advanced Prostate Cancer
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.
ascopubs.org5d
Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALL
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Treatment stratification in ALL ...